In preclinical models, NDC-1308 activates genes responsible for progenitor cell differentiation, leading to the production of myelin, the protective covering that is damaged in patients with demyelinating diseases such as MS and ODS. Specific steps include: Progenitor cells (1) mature into pre-oligodendrocytes, (2) which then become pre-myelinating oligodendrocytes, (3) and ultimately, myelinating oligodendrocytes (4).

NDC-1308 is a novel chemical entity, currently in late preclinical development, that is designed to address one of the root causes of MS and ODS by inducing oligodendrocyte progenitor cells (OPCs) – the precursors of oligodendrocytes – to mature into oligodendrocytes, the cells that synthesize and maintain the myelin sheath.

  • Studies in animal models suggest that NDC-1308 significantly induces remyelination of demyelinated nerves by causing a dramatic up regulation of genes in signaling pathways involved in inducing OPC differentiation, leading to myelin sheath production.
  • Our validation studies, supported in part by a research grant from the National Multiple Sclerosis Society, have reproducibly demonstrated the induction of remyelination in a mouse model of demyelination in which the neurotoxicant cuprizone was used to remove the myelin sheath from the axons (nerve fibers) of mice.

NDC-1308 is being developed for the treatment of ODS and MS.